AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22955125
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (120 mg tablet, EGb‐761) twice a day for 12 weeks
Trial: 22955125
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice a day for 12 weeks
Trial: 20028712
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg twice a day
Trial: 17684983
Drug: 10% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% albumin solution
Trial: 16084882
Drug: G972A variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G972A variant of insulin receptor substrate‐1 (IRS‐1) in women with PCOS
Trial: 12601100
Drug: Pergolide (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.15 to 0.45 mg per day)
Trial: 10029283
Drug: Natural IFNalpha,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural IFNalpha, 10 MU, i.m. daily for 2 consecutive weeks and then three times per week for the subsequent 14 weeks (total dose 560 MU)
Trial: 10029283
Drug: Natural IFNalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural IFNalpha treatment
Trial: 6095655
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg as a single nighttime dose
Trial: 31605515
Drug: HAL-based walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAL-based walking therapy
Trial: 28393417
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg d1) in combination with granisetron and dexamethasone
Trial: 28393417
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg d1; 80 mg d2-d3) in combination with granisetron and dexamethasone
Trial: 25844619
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement (45-g daily)
Trial: 25844619
Drug: Isocaloric maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric maltodextrin supplement (control)
Trial: 24517028
Drug: Paracetamol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1.0 g) co-administered with ferrous sulphate (300 mg)
Trial: 24517028
Drug: Paracetamol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1.0 g) alone
Trial: 12215864
Drug: Active gallium-arsenide
RxNorm normalized name: GALLIUM ARSENIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gallium-arsenide (Ga-As) laser therapy
Trial: 12215864
Drug: Amitriptyline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline therapy (10 mg daily at bedtime for 8 weeks)
Trial: 2782506
Drug: Other conditions
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other conditions designed to supplement the manual plus television
Trial: 780001
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate aerosol, 800 mcg daily
Trial: 29788815
Drug: Magnesium loading
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium loading dose (7.5 g of magnesium sulfate in 500 mL normal saline as intravenous infusion over an 8-hour period)
Trial: 29788815
Drug: Magnesium loading
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium loading dose
Trial: 25384603
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) group, 150 mg/kg IV bolus at anaesthetic induction followed by continuous infusion at 150 mg/kg per day for 24 hours.
Trial: 11212970
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement (both active groups)
Trial: 9609581
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline 5 mg every 6 hours for 24 hours
Trial: 31421469
Drug: GP induction
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP induction chemotherapy
Trial: 28645713
Drug: Q6 dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q6 dosing strategy (n=4)
Trial: 28645713
Drug: Q8 dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q8 dosing strategy (n=6)
Trial: 28645713
Drug: Q24 dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q24 dosing strategy (n=6)
Trial: 15089817
Drug: Nifedipine controlled-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine controlled-release (CR) 20-40 mg daily
Trial: 15089817
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 20-40 mg daily
Trial: 23705344
Drug: Multimodal Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal Music Therapy (MMT)
Trial: 17845588
Drug: Xolair (omalizumab)
RxNorm normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xolair (omalizumab) treatment for 6 years followed by withdrawal
Trial: 16329362
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential LASIK
Trial: 9798529
Drug: ANP (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP (7.5 ng/kg/min) infusion during high salt diet
Trial: 9798529
Drug: ANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP infusion during low salt diet
Trial: 8566922
Drug: Graphite furnace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graphite furnace atomic absorption spectrophotometry (GFAAS) method for manganese determination
Trial: 27524737
Drug: Transcutaneous interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transcutaneous interferential electrical stimulation plus behavioral therapy
Trial: 29747432
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy alone
Trial: 25794202
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of lidocaine 2%
Trial: 25794202
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of lidocaine 2% + 1 mL of betametazone
Trial: 20537740
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine (n = 25)
Trial: 15642569
Drug: Azimilide 75
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 75 mg
Trial: 10642679
Drug: Erythromycin (divided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (divided doses for 14 days)
Trial: 1337466
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimen 1
Trial: 1337466
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimen 2
Trial: 2423794
Drug: Indoramin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (75 mg/day for 2 weeks)
Trial: 31691305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and RTW-I (COMBO)
Trial: 24241787
Drug: Both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both agents (Tamoxifen and Fenretinide)
Trial: 21178084
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d of algal DHA
Trial: 16921042
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional chemotherapy)
Trial: 1758414
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration therapy using a resorbable membrane
Trial: 1758414
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration therapy using a nonresorbable membrane
Trial: 7045255
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% acyclovir (ACV) in polyethylene glycol (PEG)
Trial: 27154976
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion plus standardized protocol of peroneal nerve electrostimulation (1 Hz frequency, 27 mA current, 200 ms pulse width)
Trial: 27154976
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion protocol alone
Trial: 27154976
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Iloprost infusion alone and Iloprost infusion plus electrostimulation)
Trial: 26370136
Drug: Aclidinium (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium (400 μg, bd)
Trial: 14685870
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (0.3 g/kg per day)
Trial: 11986017
Drug: Active mechanical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active mechanical massage by intermittent negative pressure on the abdominal wall (Cellu M50 device, LPG, Valence, France); performed daily until the seventh postoperative day.
Trial: 11986017
Drug: Active mechanical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active mechanical massage group; performed daily until the seventh postoperative day.
Trial: 9876753
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (ondansetron or metoclopramide) in males
Trial: 8541815
Drug: Ambroxol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol, 150 mg.day‐1
Trial: 2121104
Drug: 0.01 mg
RxNorm normalized name: urea 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg of recombinant human IFN‐gamma
Trial: 2121104
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg of recombinant human IFN‐gamma
Trial: 750151
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of hyperosmotic solutions made with glycerol
Trial: 31264085
Drug: Biophysical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophysical therapy (electromagnetic information transfer through aqueous system procedure every 3 months)
Trial: 31264085
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment with renin‐angiotensin‐aldosterone system inhibitors)
Trial: 29405515
Drug: BCG-PSN therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-PSN therapy (intradermal injections, twice weekly for three weeks)
Trial: 24796339
Drug: Delcasertib 50
RxNorm normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delcasertib 50 mg/h
Trial: 24796339
Drug: Delcasertib 150
RxNorm normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delcasertib 150 mg/h
Trial: 24796339
Drug: Delcasertib 450
RxNorm normalized name: Delcasertib
DrugBank: Delcasertib (DB05560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delcasertib 450 mg/h
Trial: 17663098
Drug: Scalp-acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp-acupuncture plus body-acupuncture combined with body therapy and performance therapy
Trial: 17663098
Drug: Simple body
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple body therapy and performance therapy
Trial: 10409573
Drug: Dexamethasone (Dex)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Dex) treatment at doses of 0.5 mg and 1.5 mg administered twice daily for 4.5 days
Trial: 6994477
Drug: Narcotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic medications
Trial: 31643039
Drug: Prasugrel 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 2.5 mg
Trial: 31643039
Drug: Prasugrel 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 7.5 mg
Trial: 31643039
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg and 7.5 mg (CYP2C19 intermediate metabolizers)
Trial: 25812823
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg daily for 7 days)
Trial: 17720079
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of triamcinolone acetonide (4 mg/0.1 mL)
Trial: 17720079
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (steroid group)
Trial: 15155466
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) monotherapy (serum concentrations 346‐693 microM [50‐100 microg/mL])
Trial: 15155466
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) + all-trans retinoic acid (ATRA) (80 mg/m(2)/d, days 1‐7, every other week)
Trial: 11559644
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 or 40 mg daily)
Trial: 3312553
Drug: Heparin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (low doses)
Trial: 31444663
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy ± red blood cell transfusion
Trial: 26582873
Drug: MMRII co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRII co-administered with HAV, VAR, and PCV7
Trial: 19339045
Drug: Polycap (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycap (low doses of thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20 mg, and aspirin 100 mg per day)
Trial: 16987908
Drug: Epoetin-beta (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-beta (all dosage groups)
Trial: 12810937
Drug: Valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 20 mg daily
Trial: 12810937
Drug: Valdecoxib 40
RxNorm normalized name: valdecoxib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 40 mg daily
Trial: 12810937
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg slow release twice daily
Trial: 29950182
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g single dose, administered 1 day before surgery)
Trial: 29950182
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single dose, administered 1 day before surgery)
Trial: 22155918
Drug: HIV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV RNA >5 log(10) copies/ml
Trial: 19109315
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for non-specific low back pain
Trial: 19109315
Drug: Treatments with
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments with large effects (>20 points)
Trial: 17890232
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart twice daily
Trial: 11682378
Drug: Esmolol (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (105 g x kg(‐1) x min(‐1)) and Nitroglycerin (1‐6 mg/h)
Trial: 29395965
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg emedastine patch
Trial: 29395965
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg emedastine patch
Trial: 29395965
Drug: Levocetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (5 mg tablet)
Trial: 25372846
Drug: Risperidone or
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone or aripiprazole (12 weeks treatment)
Trial: 9312922
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 5.2 g daily for 12 weeks
Trial: 8513986
Drug: Metoclopramide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide with fluoxetine
Trial: 2880066
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 500 mg, three times a day for 10 days
Trial: 2880066
Drug: Intravenous azlocillin
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous azlocillin 5 g and gentamicin 80 mg, three times a day for 10 days
Trial: 14656276
Drug: TEC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (paclitaxel 175 mg/m2, carboplatin AUC 5, epirubicin 75 mg/m2)
Trial: 14656276
Drug: TC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (paclitaxel 175 mg/m2, carboplatin AUC 5)
Trial: 8402762
Drug: Celiprolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (300 mg/day)
Trial: 31960175
Drug: Exposure-based SAD-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based SAD-specific group cognitive behavioral therapy (CBT), n=31
Trial: 29502984
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg once daily at bedtime
Trial: 15984576
Drug: Beta-adrenoblockers (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoblockers (administered in both groups)
Trial: 12753444
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of morphine (40 micro g x kg‐1 initial bolus, 10 micro g.ml‐1 infusion)
Trial: 12753444
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of clonidine (1 micro g x kg‐1 initial bolus, 0.6 micro g.ml‐1 infusion)
Trial: 10069510
Drug: Tiotropium (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (once daily inhalation for 28 days)
Trial: 8913544
Drug: Losartan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan with low-dose hydrochlorothiazide
Trial: 6298934
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of cotrimoxazole
Trial: 6298934
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of amoxycillin
Trial: 6298934
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of Na-bicarbonate
Trial: 30203839
Drug: Siltuximab (anti-IL6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (anti-IL6 monoclonal antibody)
Trial: 23336746
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream (0.05%) and Aloe vera topical gel (50%)
Trial: 23336746
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream (0.05%) and vehicle
Trial: 20938821
Drug: Open operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open operative reflux therapy
Trial: 18547426
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si
Trial: 18547426
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 12 mg Si
Trial: 18547426
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 3 mg Si
Trial: 18547426
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si (subgroup analysis)
Trial: 15947831
Drug: 10% polyvinylpyrrolidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% polyvinylpyrrolidone-iodine solution